The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
 
Mohamad Bassam Sonbol
No Relationships to Disclose
 
Belal Firwana
No Relationships to Disclose
 
Zhen Wang
No Relationships to Disclose
 
Daniel H. Ahn
Consulting or Advisory Role - Celltrion (I); Merrimack
 
Mitesh J. Borad
No Relationships to Disclose
 
Issam Makhoul
Research Funding - Genentech/Roche (Inst); Newlink Genetics (Inst)
 
Ramesh K. Ramanathan
Honoraria - Cerulean Pharma; Insys Therapeutics; Novocure; Pharmacyclics; Taiho Pharmaceutical
Consulting or Advisory Role - Cerulean Pharma; Insys Therapeutics; Novocure; Pharmacyclics
Research Funding - Abbvie (Inst); Bayer (Inst); Berg Pharma (Inst); Biomarin (Inst); Boston Biomedical (Inst); Celgene (Inst); Halozyme (Inst); Merck/Schering Plough (Inst); Merrimack (Inst); Superlab Far East (Inst); Tekmira (Inst); Verastem (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Glenmark; Lilly; Merrimack; NCCN; Regeneron; Research to Practice; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Expert Testimony - Helsinn Therapeutics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen